
Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway
Keywords: Rosiglitazone; Vincristine; Cell proliferation and apoptosis; Cell cycle; Drug resistance reversal; PTEN/PI3K/AKT; Oral epidermoid carcinoma